Nuclear Localization and Intensity of Staining of Nm23 Protein is Useful Marker for Breast Cancer Progression

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2008 May 6

PMID 18454879

Citations 7

Authors

Nawfal I Ismail

Gurjeet Kaur

Hasnah Hashim

Mohammed S Hassan

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the most common cause of cancer death in the western world. The expression differences of many proteins are associated with breast cancer progression or suppression. The purpose of the study was to determine the expression of nm23 protein in the invasion status and metastatic potential of breast cancer by using tissue microarray and to determine its role in breast cancer based on the expression of nm23 gene product.

Method: nm23 protein expression was examined by immunohistochemistry (IHC) using commercially available tissue microarray containing malignant and normal breast tissues from 216 patients.

Results: a similar percentage of cases showed positive cytoplasmic/nuclear staining for nm23 in normal breast tissue (85.7%), primary breast carcinoma node negative (97.5%) and carcinoma with lymph node metastasis (92.1%). Nuclear localization of staining for nm23 protein was higher in infiltrating ductal carcinoma (IDC) node positive (24.3%) and in matched lymph mode metastasis (18.9%) compared to IDC node negative (4.9%). Strong intensity of cytoplasmic/nucleus staining was observed in IDC node negative (42.6%), in IDC node positive (57.1%), and Infiltrating lobular carcinoma (ILC) node negative (44%) compared to normal breast tissue (16.7%).

Conclusion: nm23 protein expression appears widely expressed in normal breast, early and advanced breast cancer stages. Interestingly our study found that strong staining intensity and nuclear localization of nm23 protein may prove to be a useful marker of breast cancer progression.

Citing Articles

Nuclear enhances the malignant behavior of A549 cells and impacts lung adenocarcinoma patient prognosis.

Xu M, Liu Y, Kuang X, Pu Y, Jiang Y, Zhao X iScience. 2024; 27(7):110286.

PMID: 39055952 PMC: 11269300. DOI: 10.1016/j.isci.2024.110286.

Nuclear functions of NME proteins.

Puts G, Leonard M, Pamidimukkala N, Snyder D, Kaetzel D Lab Invest. 2017; 98(2):211-218.

PMID: 29058704 PMC: 6136249. DOI: 10.1038/labinvest.2017.109.

Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies.

Okabe-Kado J, Kasukabe T, Kaneko Y Adv Hematol. 2011; 2012:879368.

PMID: 21941554 PMC: 3175692. DOI: 10.1155/2012/879368.

Mass spectrometry detection of histidine phosphorylation on NM23-H1.

Lapek Jr J, Tombline G, Friedman A J Proteome Res. 2010; 10(2):751-5.

PMID: 21121676 PMC: 3033978. DOI: 10.1021/pr100905m.

Antimetastatic role of Smad4 signaling in colorectal cancer.

Zhang B, Halder S, Kashikar N, Cho Y, Datta A, Gorden D Gastroenterology. 2009; 138(3):969-80.e1-3.

PMID: 19909744 PMC: 2831103. DOI: 10.1053/j.gastro.2009.11.004.

References

Bertheau P, Steinberg S, Merino M . C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol. 1998; 29(4):323-9. DOI: 10.1016/s0046-8177(98)90111-3. View

Chen S, Wu Y, Shieh H, Yen C, Shen J, Lin K . P53 is a regulator of the metastasis suppressor gene Nm23-H1. Mol Carcinog. 2003; 36(4):204-14. DOI: 10.1002/mc.10110. View

Kamby C . The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. Cancer Treat Rev. 1990; 17(1):37-61. DOI: 10.1016/0305-7372(90)90075-q. View

Hennessy C, Henry J, May F, Westley B, Angus B, Lennard T . Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst. 1991; 83(4):281-5. DOI: 10.1093/jnci/83.4.281. View

Yamaguchi A, Urano T, Goi T, Takeuchi K, Niimoto S, Nakagawara G . Expression of human nm23-H1 and nm23-H2 proteins in hepatocellular carcinoma. Cancer. 1994; 73(9):2280-4. DOI: 10.1002/1097-0142(19940501)73:9<2280::aid-cncr2820730908>3.0.co;2-3. View

Mao H, Liu H, Fu X, Fang Z, Abrams J, Worsham M . Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer. Int J Oncol. 2001; 18(3):587-91. DOI: 10.3892/ijo.18.3.587. View

Han S, Yun I, Noh D, Choe K, Song S, Chi J . Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol. 1997; 65(1):22-7. DOI: 10.1002/(sici)1096-9098(199705)65:1<22::aid-jso5>3.0.co;2-q. View

Royds J, Rees R, Stephenson T . nm23--a metastasis suppressor gene?. J Pathol. 1994; 173(3):211-2. DOI: 10.1002/path.1711730302. View

Gazzeri S, Brambilla E, NEGOESCU A, Thoraval D, Veron M, Moro D . Overexpression of nucleoside diphosphate/kinase A/nm23-H1 protein in human lung tumors: association with tumor progression in squamous carcinoma. Lab Invest. 1996; 74(1):158-67. View

10.

Steeg P, Bevilacqua G, Kopper L, Thorgeirsson U, Talmadge J, Liotta L . Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988; 80(3):200-4. DOI: 10.1093/jnci/80.3.200. View

11.

Ozeki Y, Takishima K, Mamiya G . Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: association with tumor progression in Clara cell type. Jpn J Cancer Res. 1994; 85(8):840-6. PMC: 5919568. DOI: 10.1111/j.1349-7006.1994.tb02956.x. View

12.

Martinez J, Prevot S, Nordlinger B, Nguyen T, Lacarriere Y, Munier A . Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut. 1995; 37(5):712-20. PMC: 1382880. DOI: 10.1136/gut.37.5.712. View

13.

Nakamori S, Ishikawa O, Ohhigashi H, Kameyama M, Furukawa H, Sasaki Y . Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion. Clin Exp Metastasis. 1993; 11(2):151-8. DOI: 10.1007/BF00114973. View

14.

Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A . Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer. 1994; 73(12):2913-21. DOI: 10.1002/1097-0142(19940615)73:12<2913::aid-cncr2820731207>3.0.co;2-l. View

15.

Tokunaga Y, Urano T, Furukawa K, Kondo H, Kanematsu T, Shiku H . Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer. 1993; 55(1):66-71. DOI: 10.1002/ijc.2910550113. View

16.

Belev B, Aleric I, Vrbanec D, Petrovecki M, Unusic J, Jakic-Razumovic J . Nm23 gene product expression in invasive breast cancer--immunohistochemical analysis and clinicopathological correlation. Acta Oncol. 2002; 41(4):355-61. DOI: 10.1080/028418602760169406. View

17.

Engel M, Theisinger B, Seib T, Seitz G, Huwer H, Zang K . High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages. Int J Cancer. 1993; 55(3):375-9. DOI: 10.1002/ijc.2910550306. View

18.

Xerri L, Grob J, Battyani Z, Gouvernet J, Hassoun J, Bonerandi J . NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br J Cancer. 1994; 70(6):1224-8. PMC: 2033668. DOI: 10.1038/bjc.1994.477. View

19.

Hirayama R, Sawai S, Takagi Y, Mishima Y, Kimura N, Shimada N . Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J Natl Cancer Inst. 1991; 83(17):1249-50. DOI: 10.1093/jnci/83.17.1249. View

20.

Bevilacqua G, Sobel M, Liotta L, Steeg P . Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res. 1989; 49(18):5185-90. View